Marshall Wace’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$75.7M Buy
1,333,207
+1,154,671
+647% +$51.2M 0.06% 265
2026
Q1
$5.3M Sell
178,536
-38,635
-18% -$1.15M 0.01% 1275
2025
Q4
$8.3M Sell
217,171
-372,880
-63% -$12.1M 0.01% 940
2025
Q3
$14.1M Sell
590,051
-152,674
-21% -$2.87M 0.01% 798
2025
Q2
$11M Buy
+742,725
New +$12.3M 0.01% 806
2024
Q4
Sell
-111,341
Closed -$1.56M 3016
2024
Q3
$1.56M Buy
+111,341
New +$1.16M ﹤0.01% 1463
2023
Q4
Sell
-73,332
Closed -$656K 2622
2023
Q3
$656K Buy
+73,332
New +$1.03M ﹤0.01% 1635
2023
Q2
Sell
-214,498
Closed -$4.82M 2976
2023
Q1
$4.82M Buy
+214,498
New +$4.56M 0.01% 1015
2022
Q1
Sell
-6,866
Closed -$213K 4033
2021
Q4
$213K Sell
6,866
-45,441
-87% -$1.28M ﹤0.01% 3141
2021
Q3
$1.27M Buy
+52,307
New +$961K 0.01% 1861
2021
Q2
Sell
-174,193
Closed -$4.35M 3105
2021
Q1
$4.35M Buy
+174,193
New +$4.81M 0.02% 915
2020
Q3
Sell
-98,976
Closed -$2.02M 1930
2020
Q2
$2.02M Buy
+98,976
New +$1.58M 0.01% 791
2016
Q3
Sell
-90,194
Closed -$1.61M 1141
2016
Q2
$1.61M Buy
90,194
+71,952
+394% +$1.16M 0.01% 632
2016
Q1
$249K Buy
+18,242
New +$277K ﹤0.01% 950

Other funds holding TVTX

Marshall Wace's TVTX Position: Q2 2026 in Review

Marshall Wace increased its Travere Therapeutics (TVTX) stake by 647% in Q2 2026, buying an estimated $51.2M and bringing the position to 1,333,207 shares worth $75.7M. The position accounts for 0.06% of the portfolio, ranked #265.

Marshall Wace first reported a position in TVTX in Q1 2016 and has held it in 14 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Marshall Wace held 1,333,207 shares of Travere Therapeutics worth $75.7M as of Q2 2026.
  • Marshall Wace bought 1,154,671 Travere Therapeutics shares in Q2 2026, an estimated $51.2M.
  • Travere Therapeutics made up 0.06% of Marshall Wace's portfolio in Q2 2026, its #265 holding.
  • Marshall Wace first reported a position in Travere Therapeutics in Q1 2016 and has held it in 14 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.